home / stock / hbpcf / hbpcf news

HBPCF News and Press, Helix Biopharma Corp From 06/14/23

Stock Information
Company Name: Helix Biopharma Corp
Stock Symbol: HBPCF
Market: OTC
Website: helixbiopharma.com
Menu
HBPCF HBPCF Quote HBPCF Short HBPCF News HBPCF Articles HBPCF Message Board
Get HBPCF Alerts

News, Short Squeeze, Breakout and More Instantly...
HBPCF - Helix BioPharma Corp. Announces Fiscal 2023 Third Quarter Results

--News Direct-- Toronto, Ontario – TheNewswire – June 14, 2023 - Helix BioPharma Corp. (TSX:HBP), (“Helix” or the “Company”), a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology based on its propr...
HBPCF - Helix Biopharma Corp. Announces Fiscal 2023 Second Quarter Results

--News Direct-- Toronto, ON - TheNewswire - March 15, 2023 - Helix BioPharma Corp. (TSX:HBP), (“Helix” or the “Company”), a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology based on its proprietary technologic...

HBPCF - Helix Biopharma Corp. Reports Voting Results

--News Direct-- Toronto, Ontario – TheNewswire – January 24, 2023 - Helix BioPharma Corp. (TSX:HBP) (“Helix” or the “Company”), a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology, based on its propri...

HBPCF - Helix Biopharma Corp. Announces Grant & Cancellation of Stock Options

--News Direct-- Toronto, ON - TheNewswire - January 9, 2023 - Helix BioPharma Corp. (TSX:HBP) (“Helix” or the “Company”), a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology, based on its proprietary technological ...
HBPCF - Helix BioPharma Corp. Announces Fiscal 2023 First Quarter Results

--News Direct-- Toronto, Ontario – Thenewswire – December 14, 2022 – Helix BioPharma Corp. (TSX:HBP), (“Helix” or the “Company”), a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology based o...

HBPCF - Helix BioPharma appoints Jacek Antas as CEO

Helix BioPharma ( OTCPK:HBPCF ) said Thursday Jacek Antas has been appointed as CEO to replace Artur Gabor with immediate effect. Gabor resigned as CEO and director. Antas has been on the board since April and has over 25 years of experience in the financial services industry...

HBPCF - Helix Biopharma Corp. Announces Board & Management Changes

--News Direct-- Toronto, ON – TheNewswire -  December 8, 2022 - Helix BioPharma Corp. (TSX:HBP) (“Helix” or the “Company”), a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology, based on its propriet...
HBPCF - Helix Biopharma Corp. Closes Private Placement of CAD $4.62 Million

(TheNewswire) NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES Toronto, Ontario – TheNewswire – November 3, 2022 - Helix BioPharma Corp. (TSX:HBP) (“Helix” or the “...

HBPCF - Helix Biopharma GAAP EPS of -$0.04

Helix Biopharma press release ( OTCPK:HBPCF ): FY GAAP EPS of -$0.04. Net cash of $3.25M For further details see: Helix Biopharma GAAP EPS of -$0.04

HBPCF - HELIX BIOPHARMA CORP. Announces Fiscal 2022 Year-End Results

--News Direct-- Toronto, Ontario – TheNewswire – November 1, 2022 - Helix BioPharma Corp. (TSX:HBP), (“Helix” or the “Company”), a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology based on ...
Previous 10 Next 10